Ursodeoxycholic acid ameliorates cell migration retarded by the SARS-CoV-2 spike protein in BEAS-2B human bronchial epithelial cells
Authors:
Open Access
- 25 April 2022
- journal article
- research article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 150, 113021
Abstract
No abstract availableKeywords
Funding Information
- National Research Foundation of Korea
- Ministry of Science, ICT and Future Planning (2021R1A4A5033289)
This publication has 31 references indexed in Scilit:
- Ursodeoxycholic acid suppresses eosinophilic airway inflammation by inhibiting the function of dendritic cells through the nuclear farnesoid X receptorAllergy, 2012
- IL‐6 augmented motility of airway epithelial cell BEAS‐2B via Akt/GSK‐3β signaling pathwayJournal of Cellular Biochemistry, 2012
- The Airway Epithelium is Central to the Pathogenesis of AsthmaAllergology International, 2008
- Airway Epithelial Repair, Regeneration, and Remodeling after Injury in Chronic Obstructive Pulmonary DiseaseProceedings of the American Thoracic Society, 2006
- Conformational States of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein EctodomainJournal of Virology, 2006
- Innate Immunity in the LungsProceedings of the American Thoracic Society, 2005
- The SARS-CoV S glycoproteinCellular and Molecular Life Sciences, 2004
- BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasoneBlood, 2004
- Ursodeoxycholic acid in cholestatic liver disease: Mechanisms of action and therapeutic use revisitedHepatology, 2002
- Trefoil Factor Family–Peptides Promote Migration of Human Bronchial Epithelial CellsAmerican Journal of Respiratory Cell and Molecular Biology, 2001